European Patent Office Allows Advaxis, Inc./University of Pennsylvania Modified LLO Patent
8/24/2010 10:15:44 AM
NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)--Advaxis, Inc., (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Lm) immunotherapy company, has been notified by the European Patent Office that patent application WO2001/072329, for the use of Prokaryotic PEST-Like Peptides for Enhancing Immunogenicity of Antigen has been allowed for issuance. This patent will be #1,303,299 when granted, and will be licensed exclusively to Advaxis by the University of Pennsylvania. It extends protection for Advaxis’ use of proprietary antigen-adjuvant fusion proteins beyond Listeria to viral and DNA vaccine vectors as well. This will provide patent protection to 2025.